Register Now: Image-Based Risk: The Next Frontier in Breast Cancer Screening
|Videos|June 27, 2023

Helen Nadel, MD, FRCPC, on Imperatives for Nuclear Medicine and Molecular Imaging

Dr. Nadel was announced as president of SNMMI for the 2023-2024 term at the 2023 SNMMI annual meeting taking place in Chicago.

Nuclear medicine, like many subspecialties, is facing a workforce crisis. The lack of incoming residents, techs, researchers, and other medical staff is hitting at a particularly poor time, as the role of nuclear medicine and molecular imaging is rapidly expanding with newfound applications in oncology, neurodegenerative disorders, and beyond.

The lack of staffing is top of mind for the Society of Nuclear Medicine and Molecular Imaging's incoming president Helen Nadel, MD, FRCPC, who began her year-long term at this year's SNMMI Annual Meeting, taking place June 24-27, 2023 in Chicago.

Dr. Nadel, who is director of pediatric nuclear medicine at Lucile Packard Children’s Hospital at Stanford and clinical professor of radiology at the Stanford School of Medicine, told Diagnostic Imaging that recruitment efforts are in full effect, with targeted programs being rolled out that focus on early education opportunities. For instance, the society held an information fair for interested high school students during the annual meeting, where children and their parents were welcome to tour exhibits and learn more about the specialty.

Dr. Nadel and other SNMMI leadership are also focused on boosting the profile of nuclear medicine, molecular imaging, and theranostics globally by partnering with other organizations and associations in the space to produce best practice guidelines and appropriate use critieria.

Click here for more coverage of SNMMI 2023.


Related to this article

Emerging Research Insights and New Advances in Neuroradiology
Catch up on key neuroradiology news and research from the past month, including recently published studies involving white matter hyperintensity findings on brain MRI, MRI-enhanced amyloid PET and the newly FDA-approved PET agent floretyrosine F18 for glioma imaging.
Current Perspectives on Integrating AI into Radiology
In a recent interview with Diagnostic Imaging, Joseph Cavallo, MD, MBA, offered insights on post-deployment monitoring with AI, the potential for improved workflow efficiency and the ongoing challenge of balancing essential clinical skills and AI literacy in the training of radiology residents and fellows.
Radiology and Building the Alzheimer’s Care Pathway of the Future
Given the increasing prevalence of Alzheimer’s disease and a staggering number of people with dementia who are undiagnosed, this author discusses five essential keys for radiologists and their colleagues to facilitate earlier detection, precision care treatment and monitoring to help ensure timely care and intervention.